Early experience with the contraceptive use of Depot Medroxyprogesterone Acetate in an inner-city clinic population

Family Planning Perspectives

Volumn 28, Issue 4, 1996, Pages 174-178

  Polaneczky, Margaret ^a   Guarnaccia, Michael ^b   Alon, Jamie ^c   Wiley, Jennifer ^b  

^a Obstetrics and Gynecology Clinic   (United States)

^b Department of Obstetrics and Gynecology ^*  (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MEDROXYPROGESTERONE ACETATE; ORAL CONTRACEPTIVE AGENT;

ABDOMINAL PAIN; ADOLESCENT; ADULT; ARTICLE; CONDOM; CONTRACEPTION; FEMALE; HEADACHE; HUMAN; MENSTRUATION DISORDER; NAUSEA; ORAL DRUG ADMINISTRATION; WEIGHT GAIN;

ACCEPTOR CHARACTERISTICS; ACCEPTORS; AMERICAS; BIOLOGY; BODY WEIGHT; CONTRACEPTION; CONTRACEPTION CONTINUATION; CONTRACEPTION TERMINATION; CONTRACEPTIVE AGENTS, FEMALE--SIDE EFFECTS; CONTRACEPTIVE AGENTS, PROGESTIN--SIDE EFFECTS; CONTRACEPTIVE AGENTS--SIDE EFFECTS; CONTRACEPTIVE METHODS; CONTRACEPTIVE USAGE; DEPO-PROVERA--SIDE EFFECTS; DEVELOPED COUNTRIES; DISEASES; ECONOMIC FACTORS; FAMILY PLANNING; FAMILY PLANNING PROGRAMS; INJECTABLES; LOW INCOME POPULATION--WOMEN; MEDROXYPROGESTERONE ACETATE--SIDE EFFECTS; MENSTRUATION DISORDERS; NEW YORK; NORTH AMERICA; NORTHERN AMERICA; PHYSIOLOGY; RESEARCH METHODOLOGY; SAMPLING STUDIES; SOCIAL CLASS; SOCIOECONOMIC FACTORS; SOCIOECONOMIC STATUS; STUDIES; SURVEYS; UNITED STATES;

ADOLESCENT; ADULT; CONTRACEPTIVE AGENTS, FEMALE; DELAYED-ACTION PREPARATIONS; FEMALE; HUMANS; LIFE TABLES; MEDROXYPROGESTERONE 17-ACETATE; MENSTRUATION DISTURBANCES; NEW YORK CITY; PATIENT COMPLIANCE; PREGNANCY; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; WEIGHT GAIN;

EID: 33749297193     PISSN: 00147354     EISSN: None     Source Type: Journal    
DOI: 10.2307/2136195     Document Type: Article

References (22)

1. M. Klitsch, "Injectable Hormones and Regulatory Controversy: An End to the Long-Running Story?" Family Planning Perspectives, 25:37-40,1993.
2. F. Isart et al., "Use of Injectable Progestin (Medroxyprogesterone Acetate) in Adolescent Health Care," Comtraception, 46:41-18, 1992;
3. and A.M. Kaunitz and A. Rosenfield, "Injectable Contraception with DMPA: Current Status," Drugs, 45:857-8651993.
4. P. C. Schwallie and J. R Assenzo, "Contraceptive UseEfficacy Study Utilizing Medroxyprogesterone Acetate Administered as an Intramuscular Injection Once Every 90 Days," Fertility and Sterility, 24331-339,1973.
5. E. B. Connell, "DMPA: Clinical Experience in the United States," Female Patient, 19:91-102,1994.
6. F. Vrazo, "Injectable Birth Control Taps a Vein of Excitement," Philadelphia Inquirer, Nov. 8,1994, p. Al.
7. J. Ipsen and P. Feigl, Bancroft's Introduction to Biostatistics, second ed., Harper & Row, New York, 1970, pp. 153-162.
8. E. T. Lee, Statistical Methods for Survival Data Analysis, second ed., John VViley and Sons, New York, 1992, pp. 105-107
9. R. R. Sokal and F.J. Rohlf, Introduction to Biostatistics, second ed., W. H. Freeman, New York, 1987, pp. 112-114.
10. J. H. Zar, Biostatistical Analysis, second ed., PrentissHall, Englewood Cliffs, N. J., 1984, pp. 150-153.
11. Ibid., pp. 176-179.
12. I. S. Fraser and E. VVeisberg, "A Comprehensive Review of Injectable Contraception with Special Emphasis on DMPA," Medical Journal of Australia (Supplement), 1:1-19,1981;
13. and S. Jeppsson, "Experience with Depot-Medroxyprogesterone Acetate (DMPA) as a Contraceptive Agent," Ada Obstetricia et Gymcologica Scandinavica, 51:257-265 1972.
14. World Health Organization (WHO) Special Programme of Research, Development and Research Training in Human Reproduction, Task Force on Long-Acting Systemic Agents for Fertility Regulation, "A Multicentered Phase III Comparative Clinical Trial of Depot-Medroxyprogesterone Acetate Given ThreeMonthly at Doses of 100 mg or 150 mg: 1. Contraceptive Efficacy and Side-Effects," Contraception, 34224-23519S6.
15. S. Soichet, "DMPA (Medroxyprogesterone Acetate) as a Female Contraceptive Agent," International Journal of Fertility, 14:33-3a 1969.
16. A.M. Kaunitz, "InjectableContraception," Clinical Obstetrics and Gynecology, 32:356-368, 1989;
17. and G. Leiman, "Depo-Medroxyprogesterone Acetate as a Contraceptive Agent: Its Effect on Weight Gain and Blood Pressure," American Journal of Obstetrics and Gynecology, 114:97-102,1972.
18. WHO Special Programme of Research, Development and Research Training in Human Reproduction, Task Force on Long-Acting Agents for the Regulation of Fertility, "Multinational Cooperative Clinical Trial of LongActing Injectable Contraceptives: Norethisterone Enanthate Given in Two Dosage Regimens and Depot Medroxyprogesterone Acetate, Final Report," Contraception, 28:1-20,1983.
19. D. R Mishell et al., "Contraception with an Injectable Progestin: A Study of Its Use in Postpartum Women," American Journal of Obstetrics and Gynecology, 101:1046-1053,1968.
20. R. Mainwaring et al., "Metabolic Parameter, Bleeding, and Weight Changes in U. S. Women Using ProgestinOnly Contraceptives," Contraception, 51:149-153,1995;
21. and L. L. Moore, "Comparative Study of One-Year Weight Gain Among Users of Medroxyprogesterone Acetate, Levonorgestrel Implants and Oral Contraceptives," Contraception, 52:215-220,1995.
22. I. Fraser and G. J. Dennerstein, "DMPA Use in an Australian Metropolitan Practice," Medical Journal of Australia, 160:553-556,1994.